In an adult patient without severe hepatic impairment, seizures, or hypersensitivity, which muscle relaxant—baclofen, tizanidine, or cyclobenzaprine—is the least sedating?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Baclofen is the Least Sedating Muscle Relaxant Among the Three Options

Among baclofen, tizanidine, and cyclobenzaprine, baclofen appears to be the least sedating option, though all three carry significant sedation risk. However, this recommendation comes with important caveats about comparative sedation profiles and overall safety considerations.

Comparative Sedation Profiles

Cyclobenzaprine: Most Sedating

Cyclobenzaprine is structurally identical to amitriptyline and carries the highest sedation burden 1, 2. The FDA label documents that drowsiness is a consistent adverse effect, with anticholinergic properties (confusion, hallucinations, drowsiness) being prominent 2. In clinical practice, cyclobenzaprine's sedative effects are comparable to tricyclic antidepressants 3.

Tizanidine: Highly Sedating

Tizanidine demonstrates dose-dependent sedation as a primary adverse effect 1, 4. The FDA label specifically warns that 48% of patients in controlled trials reported sedation, with 10% rating it as severe 4. In a single-dose study, 92% of patients receiving 16 mg reported drowsiness, with effects peaking 1.5 hours post-dose and persisting for 6 hours 4. The 2021 SPAQI guidelines note "significant sedative and hypotensive effects" requiring avoidance in elderly patients 1.

Baclofen: Least Sedating (Relatively)

While baclofen does cause sedation and somnolence as adverse effects 3, 5, comparative studies suggest it produces less sedation than the alternatives. In direct comparison trials, tizanidine was found to cause more somnolence than baclofen, though baclofen caused more muscle weakness 6, 7. The 2009 JAGS guideline notes baclofen's "common side effects of dizziness, somnolence" but does not emphasize sedation as prominently as with other agents 3.

Critical Safety Considerations

Why This Ranking May Be Misleading

Recent evidence challenges the assumption that baclofen is safer overall. A 2025 retrospective cohort study of 87,896 older adults found that baclofen carried a 69% greater risk of serious injury (fractures, falls, brain injury) compared to cyclobenzaprine (aHR 1.69,95% CI 1.51-1.88), while tizanidine showed 34% greater risk (aHR 1.34,95% CI 1.11-1.62) 8. This suggests that focusing solely on sedation may miss broader safety concerns.

Withdrawal Risk with Baclofen

Baclofen carries life-threatening withdrawal risks that the other agents do not 1. Abrupt discontinuation can cause seizures, hallucinations, delirium, fever, and tachycardia. Intrathecal baclofen withdrawal can lead to rhabdomyolysis, multiorgan failure, and death 1.

Clinical Decision Algorithm

For patients prioritizing minimal sedation:

  1. First choice: Baclofen - Start low (5-10 mg) and titrate slowly to minimize dizziness/somnolence 3
  2. Avoid: Cyclobenzaprine - Highest anticholinergic and sedative burden
  3. Avoid: Tizanidine - 48% sedation rate with dose-dependent effects

However, for overall safety in older adults:

  • Consider that none of these agents may be optimal given the 2025 evidence showing increased injury risk with baclofen and tizanidine compared to cyclobenzaprine 8
  • The 2023 Beers Criteria excludes baclofen and tizanidine from the "avoid" list, but newer data suggests this exclusion may need reconsideration 8

Common Pitfalls

  1. Assuming "less sedating" equals "safer" - Baclofen's lower sedation profile is offset by severe withdrawal risks and recent injury data
  2. Ignoring drug interactions - Tizanidine has significant CYP1A2 interactions causing hypotension, bradycardia, and enhanced sedation 1
  3. Overlooking hepatic impairment - Cyclobenzaprine and tizanidine require dose reduction or avoidance in hepatic dysfunction 1, 2
  4. Failing to taper - All three require slow tapering to prevent withdrawal, but baclofen withdrawal is potentially fatal 1

The perioperative guidelines recommend continuing baclofen and tizanidine through surgery but holding cyclobenzaprine on the day of operation 1, which indirectly supports their relative safety profiles in specific contexts.

References

3
Guideline

pharmacological management of persistent pain in older persons.

Journal of the American Geriatrics Society (JAGS), 2009

6
Research

Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1988

Related Questions

Should a patient who has been taking cyclobenzaprine (Flexeril) be tapered off before initiating tizanidine?
For an adult patient without contraindications, which oral muscle relaxant—methocarbamol, cyclobenzaprine (Flexeril), or tizanidine—is preferred for acute musculoskeletal spasm, and what are the recommended dosing and major contraindications?
In an adult patient without significant hepatic, renal, or cardiovascular disease, which medication, cyclobenzaprine or tizanidine, is more effective for muscle spasms?
In a patient with levator ani syndrome or hypertonic pelvic floor who did not respond to baclofen, is tizanidine a suitable alternative, or does its mechanism of action overlap with baclofen such that it would not provide additional benefit?
How do tizanidine and cyclobenzaprine compare as oral muscle relaxants for acute musculoskeletal spasm in adults, including dosing, contraindications, and side effects?
What is the first-line treatment for a patient with irritable bowel syndrome with constipation (IBS-C)?
What Glasgow Coma Scale score defines a good candidate for surgical excision of a brain hemangioma?
In a patient with severe left‑ventricular systolic dysfunction presenting with chest pain, which analgesic—fentanyl or morphine—is the drug of choice?
For a patient with symptomatic sinus bradycardia, after ruling out all reversible causes, whose symptoms limit his ability to work as a carpenter and who has been on work restrictions for a month, what is the recommended definitive therapy?
What is an appropriate prescribing regimen for etizolam in a young adult with anxiety and insomnia, including dose, frequency, duration, and whether it can be stopped abruptly?
Are there any FDA‑approved estrogen-containing topical creams for facial use?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.